These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 7486869)

  • 1. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
    Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
    Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA; Holford NH
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
    Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
    Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sinemet CR in Parkinson's disease.
    Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):37-45. PubMed ID: 8572664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Hoey M; Kutt H; McDowell FH
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
    Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A;
    Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.